Evicenter
P&T meetings

Bezuclastinib

Nonadvanced systemic mastocytosis

Manufacturer
Cogent Biosciences
Regulatory submission
NDA submitted December 2025
Last updated
62 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Nonadvanced systemic mastocytosis

Economic burden and healthcare resource utilization

3 evidence topics · 3 sources

U.S. healthcare costs: nonadvanced SM versus matched non-SM controls

“Mean±SD (median) post-index total medical costs were $24,588±51,385 ($9,019) vs. $14,419±33,449 ($4,035) (P<0.001).” (opens the source at this quote in a new tab)

Healthcare resource utilization and medication burden

“Patients with ISM take more classes of medications compared to control patients (14.68 vs 5.79)” (opens the source at this quote in a new tab)

SUMMIT: changes in best supportive care medication use

“50% of patients reported a dose reduction and/or discontinuation of best supportive care medicines during the treatment period at week 48” (opens the source at this quote in a new tab)